Cytotoxic and targeted therapy for BRCA1/2-driven cancers

Tumors arising in BRCA1/2 germline mutation carriers usually demonstrate somatic loss of the remaining BRCA1/2 allele and increased sensitivity to platinum compounds, anthracyclines, mitomycin C and poly (ADP-ribose) polymerase inhibitors (PARPi). Exposure to conventional platinum-based therapy or P...

Descripción completa

Detalles Bibliográficos
Autor principal: Imyanitov, Evgeny N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399736/
https://www.ncbi.nlm.nih.gov/pubmed/34454564
http://dx.doi.org/10.1186/s13053-021-00193-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399736/
https://www.ncbi.nlm.nih.gov/pubmed/34454564
http://dx.doi.org/10.1186/s13053-021-00193-y

Ejemplares similares